SrasV1, Main, Exploration, bibRecord, 001044

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Identifieur interne : 001044 ( Main/Exploration ); précédent : 001043; suivant : 001045

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Auteurs : Clifton Mcpherson [États-Unis] ; Richard Chubet [États-Unis] ; Kathy Holtz [États-Unis] ; Yoshikazu Honda-Okubo [Australie] ; Dale Barnard [États-Unis] ; Manon Cox [États-Unis] ; Nikolai Petrovsky [Australie]

Source :

Methods in molecular biology (Clifton, N.J.) [ 1940-6029 ] ; 2016.

RBID : pubmed:27076136

Descripteurs français

KwdFr :
- Adjuvants immunologiques, Animaux, Glycoprotéine de spicule des coronavirus (immunologie), Humains, Inuline (immunologie), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie).
MESH :
- immunologie : Glycoprotéine de spicule des coronavirus, Inuline, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- Adjuvants immunologiques, Animaux, Humains.

English descriptors

KwdEn :
- Adjuvants, Immunologic, Animals, Humans, Inulin (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus (immunology), Viral Vaccines (immunology).
MESH :
- chemical , immunology : Inulin, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical : Adjuvants, Immunologic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- Animals, Humans.

Abstract

Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.

DOI: 10.1007/978-1-4939-3387-7_14
PubMed: 27076136

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.</title>
<author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chubet, Richard" sort="Chubet, Richard" uniqKey="Chubet R" first="Richard" last="Chubet">Richard Chubet</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042</wicri:regionArea>
<wicri:noRegion>5042</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560</wicri:regionArea>
<wicri:noRegion>84322-560</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cox, Manon" sort="Cox, Manon" uniqKey="Cox M" first="Manon" last="Cox">Manon Cox</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia. nikolai.petrovsky@flinders.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042</wicri:regionArea>
<wicri:noRegion>5042</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27076136</idno>
<idno type="pmid">27076136</idno>
<idno type="doi">10.1007/978-1-4939-3387-7_14</idno>
<idno type="wicri:Area/PubMed/Corpus">000C68</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C68</idno>
<idno type="wicri:Area/PubMed/Curation">000C68</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C69</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C69</idno>
<idno type="wicri:Area/Ncbi/Merge">002C40</idno>
<idno type="wicri:Area/Ncbi/Curation">002C40</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002C40</idno>
<idno type="wicri:Area/Main/Merge">001046</idno>
<idno type="wicri:Area/Main/Curation">001044</idno>
<idno type="wicri:Area/Main/Exploration">001044</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.</title>
<author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chubet, Richard" sort="Chubet, Richard" uniqKey="Chubet R" first="Richard" last="Chubet">Richard Chubet</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042</wicri:regionArea>
<wicri:noRegion>5042</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT, 84322-560</wicri:regionArea>
<wicri:noRegion>84322-560</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cox, Manon" sort="Cox, Manon" uniqKey="Cox M" first="Manon" last="Cox">Manon Cox</name>
<affiliation wicri:level="2"><nlm:affiliation>Protein Sciences Corporation Inc, Meriden, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Sciences Corporation Inc, Meriden, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia. nikolai.petrovsky@flinders.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042</wicri:regionArea>
<wicri:noRegion>5042</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Methods in molecular biology (Clifton, N.J.)</title>
<idno type="eISSN">1940-6029</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Humans</term>
<term>Inulin (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Inuline (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Inulin</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Inuline</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus. </div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>États-Unis</li>
</country>
<region><li>Connecticut</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name>
</region>
<name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name>
<name sortKey="Chubet, Richard" sort="Chubet, Richard" uniqKey="Chubet R" first="Richard" last="Chubet">Richard Chubet</name>
<name sortKey="Cox, Manon" sort="Cox, Manon" uniqKey="Cox M" first="Manon" last="Cox">Manon Cox</name>
<name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name>
</country>
<country name="Australie"><noRegion><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name>
</noRegion>
<name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001044 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27076136
   |texte=   Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27076136" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.